CN104873893A - Blood fat reducing type medicine composition - Google Patents
Blood fat reducing type medicine composition Download PDFInfo
- Publication number
- CN104873893A CN104873893A CN201510270062.9A CN201510270062A CN104873893A CN 104873893 A CN104873893 A CN 104873893A CN 201510270062 A CN201510270062 A CN 201510270062A CN 104873893 A CN104873893 A CN 104873893A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood fat
- polyphenol
- fructus
- fat reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the technical field of medicine, particularly to a blood fat reducing type medicine composition which is composed of the following components in parts by mass: 15-30 parts of radix bupleuri, 3-10 parts of turmeric, 5-15 parts of semen cassiae, 10-30 parts of chrysanthemum, 10-20 parts of alfalfa extract, 2-8 parts of fructus piperis longi oil, 1-10 parts of persimmon polyphenol and 1-5 parts of banana skin polyphenol. The blood fat reducing type medicine composition has the following benefits: 1, the blood fat reducing type medicine composition is simple and available in raw material, low in cost and safe in medication; the added banana skin polyphenol has the remarkable blood fat reduction and antioxidation functions and can adopt the blood fat reduction and antioxidation mechanism to reduce damage to artery blood vessels so as to slow down development of AS; the added persimmon polyphenol can regulate blood fat and has the antimicrobial activity; when the persimmon polyphenol and banana skin polyphenol are compounded for application, the blood fat reduction function of the blood fat reducing type medicine composition can be greatly improved; in addition, the raw materials are easy to obtain, low in cost and harmless to the environment and humans.
Description
Technical field
The present invention relates to medical art, especially a kind of pharmaceutical composition of blood fat reducing.
Background technology
Hyperlipemia is in clinical middle genus commonly encountered diseases, and with advancing age, its sickness rate also obviously increases, particularly common in obese people.Hyperlipemia, in the pathogenesis of arteriosclerosis, coronary heart disease, plays an important role, and causes the common concern of people, the control of cardiovascular and cerebrovascular disease is brought in government utility, put on an equal footing with Prevention of Infectious Diseases in China.Over nearly 20 years, blood-fat regulating medicine is of a great variety, according to the difference of primary treatment effect, is roughly divided into two large classes: push away Statins, as simvastatin, pravastatin and chlorine cut down statin to reduce blood T-CHOL and low density lipoprotein, LDL for main head; Another kind of is reduce triglyceride for master, and with the special class of shellfish for representative, as fenofibrate and gemfibrozil etc., they are first-line drugs of control dyslipidemia, have the effect of high density lipoprotein increasing.Except some chemical drugs, the Chinese patent medicine for hyperlipidemia is also more, as SHANZHAJING JIANGZHI PIAN, extracts active component make, for stagnant card in the food stasis of blood of hyperlipidemia by Fructus Crataegi; Fat can clearing capsule, is made up of, for accumulateing disease in the phlegm-damp of hyperlipidemia Semen Lepidii, Radix Scutellariae, Fructus Crataegi, Radix Et Rhizoma Rhei, Rhizoma Alismatis, the Radix Aucklandiae; YunNan Pollen Tiendni Oral liquid, is made up of pollen of Semen Fagopyri Esculenti, Typhonium flagelliforme (Lodd.) Blume, Mel, for the syndrome of static blood blocking collaterals of hyperlipemia, class this also have a lot.
The Western medicine being used for the treatment of hyperlipemia is at present subject to everybody favor certainly because of its rapid-action and curative effect, but Western medicine has toxic and side effects in various degree, and Chinese medicine is in treatment hyperlipemia, prevent the aspects such as cardiovascular and cerebrovascular disease generation from having unique advantage, its curative effect certainly, lasting, side effect is little, is that Western medicine institute is incomparable.Particularly in differentiation of symptoms and signs for classification of syndrome, embody the flexible prescription of the traditional Chinese medical science, the therapeutic features of giving treatment in accordance with the patient’s individuality.Modern doctor generally believes genus deficiency in origin and excess in superficiality, blood stasis, the turbid category of expectorant for the understanding of hyperlipemia; Ahyperlipoidemia name of disease in Chinese medicine, clinical syndrome differentiation is attributed to caused by liver and kidney deficiency more, and insufficiency of the spleen expectorant is turbid, qi depression to blood stasis.Large multiplex liver and kidney tonifying during treatment, invigorating the spleen and benefiting QI, nourishing YIN and benefiting blood, blood circulation promoting and blood stasis dispelling, clearing away heat and loosing the bowels, eliminate indigestion and phlegm these medicines.Blood fat reducing class health product mainly fish oil class and phospholipid in the market, effect plays slow, and does not have the effect of thromboembolism preventing, thrombolytic.
Summary of the invention
The technical problem to be solved in the present invention is: overcome deficiency of the prior art, provides one to take safety, cost is low, has the pharmaceutical composition of blood fat reducing of thromboembolism preventing, thrombolytic simultaneously.
For solving the problems of the technologies described above, the technical solution used in the present invention is as follows:
A pharmaceutical composition for blood fat reducing, the mass parts of described pharmaceutical composition is composed as follows: Radix Bupleuri 15-30 part, Rhizoma Curcumae Longae 3-10 part, Semen Cassiae 5-15 part, Flos Chrysanthemi 10-30 part, Herba Medicaginis extract 10-20 part, Fructus Piperis Longi oil 2-8 part, Fructus Kaki polyphenol 1-10 part, pericarp of Fructus Musae polyphenol 1-5 part.
Further, described Fructus Kaki polyphenol adopts following methods to extract: the drip washing of Fructus Kaki Fructus Canarii dried, stripping and slicing, smash to pieces for subsequent use after peeling in bruisher, then carry out supersound extraction with the ethanol of 90% as Extraction solvent.
Further, described ultrasonic temperature is 40-45 DEG C, and ultrasonic time is 30min, and solid-liquid ratio is 1:32.
Further, described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, and scald 6-8min in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 1.5-2h, and solid-liquid ratio is 1:3.
Further, described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, and scald 6min in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 2h, and solid-liquid ratio is 1:3.
Further, described Fructus Piperis Longi oil adopts following methods to extract: use the water soaking of 30-40 DEG C extremely thoroughly, extraction by steam distillation volatile oil, collect oil content for subsequent use.
Further, the mass parts of described pharmaceutical composition is composed as follows: Radix Bupleuri 20 parts, 6 parts, Rhizoma Curcumae Longae, Semen Cassiae 10 parts, Flos Chrysanthemi 20 parts, Herba Medicaginis extract 15 parts, Fructus Piperis Longi oil 5 parts, Fructus Kaki polyphenol 6 parts, pericarp of Fructus Musae polyphenol 3 parts.
The beneficial effect of technical scheme of the present invention is adopted to be:
1, the Antilipidemic pharmaceutical compositions added in the present invention, raw material is simple and easy to get, and cost is low; Drug safety, with the addition of pericarp of Fructus Musae polyphenol in the present invention, has blood fat reducing significantly and antioxidation, pericarp of Fructus Musae polyphenol can with blood fat reducing Antioxidation Mechanism reduce arterial vascular infringement, thus delay the development of AS.
2, with the addition of Fructus Kaki polyphenol energy adjusting blood lipid in the present invention, but also there is antibacterial activity, by Fructus Kaki polyphenol and the composite use of pericarp of Fructus Musae polyphenol, greatly can improve the hypolipemic function of blood lipid-lowering medicine of the present invention, and raw material is easy to get, cost is low, harmless to Environmental insults.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention will be further described.
A pharmaceutical composition for blood fat reducing, the mass parts of described pharmaceutical composition is composed as follows: Radix Bupleuri 15-30 part, Rhizoma Curcumae Longae 3-10 part, Semen Cassiae 5-15 part, Flos Chrysanthemi 10-30 part, Herba Medicaginis extract 10-20 part, Fructus Piperis Longi oil 2-8 part, Fructus Kaki polyphenol 1-10 part, pericarp of Fructus Musae polyphenol 1-5 part.
The mass parts composition of embodiment 1-6 is in table 1.
The polyphenol of Fructus Kaki described in embodiment 1-2 adopts following methods to extract: the drip washing of Fructus Kaki Fructus Canarii dried, stripping and slicing, smash to pieces for subsequent use after peeling in bruisher, then carry out supersound extraction with the ethanol of 90% as Extraction solvent; Described ultrasonic temperature is 40 DEG C, and ultrasonic time is 30min, and solid-liquid ratio is 1:32.
Described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, and scald 6min in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 1.5, and solid-liquid ratio is 1:3.
Described Fructus Piperis Longi oil adopts following methods to extract: use the water soaking of 30-40 DEG C extremely thoroughly, extraction by steam distillation volatile oil, collect oil content for subsequent use.
The polyphenol of Fructus Kaki described in embodiment 3-4 adopts following methods to extract: the drip washing of Fructus Kaki Fructus Canarii dried, stripping and slicing, smash to pieces for subsequent use after peeling in bruisher, then carry out supersound extraction with the ethanol of 90% as Extraction solvent; Described ultrasonic temperature is 45 DEG C, and ultrasonic time is 30min, and solid-liquid ratio is 1:32.
Described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, and scald 6min in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 2h, and solid-liquid ratio is 1:3.
Described Fructus Piperis Longi oil adopts following methods to extract: use the water soaking of 30-40 DEG C extremely thoroughly, extraction by steam distillation volatile oil, collect oil content for subsequent use.
The polyphenol of Fructus Kaki described in embodiment 5-6 adopts following methods to extract: the drip washing of Fructus Kaki Fructus Canarii dried, stripping and slicing, smash to pieces for subsequent use after peeling in bruisher, then carry out supersound extraction with the ethanol of 90% as Extraction solvent; Described ultrasonic temperature is 42 DEG C, and ultrasonic time is 30min, and solid-liquid ratio is 1:32.
Described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, and scald 8min in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 1.8h, and solid-liquid ratio is 1:3.
Described Fructus Piperis Longi oil adopts following methods to extract: use the water soaking of 30-40 DEG C extremely thoroughly, extraction by steam distillation volatile oil, collect oil content for subsequent use.
Embodiment 3 is preferred forms.
Effect test:
1, zoopery: commercially available rat 70, body weight 165 ± 15g, with high lipid food (normal feedstuff 79%, cholesterol 1%, Adeps Sus domestica 10%, yolk powder 10%) feed 7 days, get tail blood, enzymatic assays serum total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C), according to TC level, animal is divided into 7 groups at random: high fat matched group, 6 test group (0.15,0.30,0.60g/Kg.bw (preparing by the method for embodiment 1-6 successively), be equivalent to 5,10,20 times of human body recommended amounts).Tested material distilled water is assigned to desired concn.From formal test, each treated animal uses high lipid food instead, and tested material group gavage gives the preparation powder of various dose, and high fat matched group gives the distilled water of same volume.Gavage amount is pressed 1ml/100g.bw and is calculated, and once a day, continuous 28 days, gets the every blood lipids index of tail hematometry.
Table 2 is the impact on rat body weight.
From table 2, with 0.15,0.30, this product preparation powder gavage of 0.60g/Kg.bw dosage gives rat 28 days, each treated animal growth, movable normal.Each dosage treated animal body weight compares with high fat matched group, no significant difference P > 0.05.
Table 3 is the impact on Serum TC, TG, HDL-C.
From table 3, with 0.15,0.30, this product formulation powder gavage of 0.60g/Kg.bw dosage gives rat 28 days, serum TC, each dosage group serum TG of low, middle dosage group obviously reduce, and compared with matched group, different have significance P < 0.05.
Although above-described embodiment describes in detail technical scheme of the present invention, but technical scheme of the present invention is not limited to above embodiment, when not departing from thought of the present invention and aim, claims limited range of the present invention all will be fallen into any change that technical scheme of the present invention is done.
Claims (7)
1. a pharmaceutical composition for blood fat reducing, is characterized in that: the mass parts of described pharmaceutical composition is composed as follows: Radix Bupleuri 15-30 part, Rhizoma Curcumae Longae 3-10 part, Semen Cassiae 5-15 part, Flos Chrysanthemi 10-30 part, Herba Medicaginis extract 10-20 part, Fructus Piperis Longi oil 2-8 part, Fructus Kaki polyphenol 1-10 part, pericarp of Fructus Musae polyphenol 1-5 part.
2. the pharmaceutical composition of a kind of blood fat reducing according to claim 1, it is characterized in that: described Fructus Kaki polyphenol adopts following methods to extract: the drip washing of Fructus Kaki Fructus Canarii dried, stripping and slicing, smashs to pieces for subsequent use in bruisher after peeling, then carry out supersound extraction with the ethanol of 90% as Extraction solvent.
3. the pharmaceutical composition of a kind of blood fat reducing according to claim 2, is characterized in that: described ultrasonic temperature is 40-45 DEG C, and ultrasonic time is 30min, and solid-liquid ratio is 1:32.
4. the pharmaceutical composition of a kind of blood fat reducing according to claim 1, it is characterized in that: described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, 6-8min is scalded in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 1.5-2h, and solid-liquid ratio is 1:3.
5. the pharmaceutical composition of a kind of blood fat reducing according to claim 4, it is characterized in that: described pericarp of Fructus Musae polyphenol adopts following extracting method to extract: Pericarpium Musae is cut into slices, 6min is scalded in boiling water, split broken homogenizing, with the ethanol ultrasonic extraction of 78%, ultrasonic temperature is 85 DEG C, ultrasonic time 2h, and solid-liquid ratio is 1:3.
6. the pharmaceutical composition of a kind of blood fat reducing according to claim 1, is characterized in that: described Fructus Piperis Longi oil adopts following methods to extract: use the water soaking of 30-40 DEG C extremely thoroughly, extraction by steam distillation volatile oil, collect oil content for subsequent use.
7. the pharmaceutical composition of a kind of blood fat reducing according to claim 1, is characterized in that: the mass parts of described pharmaceutical composition is composed as follows: Radix Bupleuri 20 parts, 6 parts, Rhizoma Curcumae Longae, Semen Cassiae 10 parts, Flos Chrysanthemi 20 parts, Herba Medicaginis extract 15 parts, Fructus Piperis Longi oil 5 parts, Fructus Kaki polyphenol 6 parts, pericarp of Fructus Musae polyphenol 3 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510270062.9A CN104873893A (en) | 2015-05-23 | 2015-05-23 | Blood fat reducing type medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510270062.9A CN104873893A (en) | 2015-05-23 | 2015-05-23 | Blood fat reducing type medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104873893A true CN104873893A (en) | 2015-09-02 |
Family
ID=53941748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510270062.9A Pending CN104873893A (en) | 2015-05-23 | 2015-05-23 | Blood fat reducing type medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873893A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100138390A (en) * | 2009-06-25 | 2010-12-31 | 신라대학교 산학협력단 | A compositon for improving or preventing hyperlipemia comprising pine tree extract |
| CN103041118A (en) * | 2013-01-28 | 2013-04-17 | 赵全成 | Composition with effects of reducing blood sugar and reducing blood lipid |
-
2015
- 2015-05-23 CN CN201510270062.9A patent/CN104873893A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100138390A (en) * | 2009-06-25 | 2010-12-31 | 신라대학교 산학협력단 | A compositon for improving or preventing hyperlipemia comprising pine tree extract |
| CN103041118A (en) * | 2013-01-28 | 2013-04-17 | 赵全成 | Composition with effects of reducing blood sugar and reducing blood lipid |
Non-Patent Citations (4)
| Title |
|---|
| 张倩倩等: "柿果多酚对高脂血症小鼠脂代谢的影响", 《食品科学》 * |
| 杨连生等: "《中国现代中医基础与临床研究》", 31 May 2004, 白山出版社 * |
| 柴瑞震: "《最有效的高血压食疗》", 30 September 2014, 黑龙江科学技术出版社 * |
| 赵磊等: "香蕉皮多酚对高脂血症大鼠降血脂作用的实验研究", 《中国实验方剂学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Chinese materia medica | |
| EP2345416B1 (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN105617286A (en) | Medicine composition which contains Chinese mugwort leaves and has blood circulation promoting and blood stasis removing functions | |
| Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
| CN104352921B (en) | Chinese medicine composition with increase bone density effect and its preparation method and application | |
| CN102973914A (en) | Chinese traditional medicine ointment for curing scalds and preparation method thereof | |
| CN102805757A (en) | Osmanthus fragrans extract, preparation method and application thereof, and medical composition for preventing or treating melancholia | |
| CN108042729A (en) | A kind of anti-acne ointment containing radix tarxaci | |
| CN104873893A (en) | Blood fat reducing type medicine composition | |
| CN105596769A (en) | Traditional Chinese medicine for treating scalds, bedsores and hemorrhoid | |
| CN101564433B (en) | Chinese medicinal composition for treating rheumatic diseases, and preparation method thereof | |
| CN104800427A (en) | Burn and scald recovery application and preparation method thereof | |
| CN104606640A (en) | Liver soothing and qi regulating medicament for treating slight fatty liver and preparation method of liver soothing and qi regulating medicament | |
| CN104825882A (en) | Pharmaceutical composition for reducing blood lipid | |
| CN106474404A (en) | A kind of medicine of preventing and treating chicken taeniasiss | |
| CN106421473A (en) | Preparation method of traditional Chinese medicine capable of reducing blood lipid | |
| DK201670336A1 (en) | A Barbados aloe scar eliminating ointment | |
| CN105770474A (en) | Lupus erythematosus resisting drug for combined immunization and preparing method and application thereof | |
| Zeeshan et al. | Medicinal Importance of Ginger (Zingiber officinale), A Systematic Review | |
| Chen | Herbology in Three Traditional Medicines for Acne | |
| CN105395827A (en) | Method for preparing composition with function of reducing blood fat | |
| Pareek et al. | Medicinal Plants Utilized in Marketed anti-Arthritic Formulations | |
| CN105125926A (en) | Medical powder for treating burns and scalds and preparation method of medical powder | |
| CN104984231A (en) | Traditional Chinese medicine for treating malaria | |
| CN104958491A (en) | Preparation method of blood circulation promoting and blood stasis removing wine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150902 |
|
| WD01 | Invention patent application deemed withdrawn after publication |